Research Information System
49th FEBS Congress, İstanbul, Turkey, 5 - 09 July 2025, vol.15, pp.243, (Summary Text)
Precision oncology aims to tailor treatments based on patient-specific tumor characteristics, and tumor organoids have proven to be powerful preclinical models for personalised drug screening. These three-dimensional (3D) structures, derived from patient tumor samples, closely mimic the histological and genetic characteristics of the original tumour and provide a reliable platform for drug response testing. In this study, we developed organoid models of liver and ovarian tumours to investigate their potential for treatment decisions. Patient-derived tumor tissue was cultured in a Matrigel matrix to form self-assembling organoids. Characterisations were confirmed by immunohistochemistry and whole exome/transcriptome sequencing for genotypic/phenotypic analyses to confirm their tumourigenic properties. High-throughput drug screening was performed using the CellTiterGlo assay to assess sensitivity to standard chemotherapies and targeted therapies. Our results show a heterogeneous response of tumor organoids to drugs, reflecting the variability observed in clinical practice. Liver tumor organoids showed a common response to bevacizumab, which is applicable according to the guidelines. Ovarian tumor organoids responded differently to platinum-based chemotherapy. Importantly, the results correlated with patient treatment outcomes, highlighting the clinical relevance of organoid-based screening. These findings highlight the potential of tumor organoids as a decision support system in precision oncology, allowing personalized treatment selection. Further validation in clinical trials could establish organoid-based drug testing as a standard approach for optimizing cancer therapies.